Loading...

argenx SE

0QW0.LLSE
Healthcare
Biotechnology
£352.20
£-4.84(-1.36%)

argenx SE (0QW0.L) Financial Performance & Income Statement Overview

Explore the financials of argenx SE (0QW0.L), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
77.27%
77.27%
Operating Income Growth
94.91%
94.91%
Net Income Growth
372.54%
372.54%
Operating Cash Flow Growth
80.31%
80.31%
Operating Margin
-0.77%
0.77%
Gross Margin
46.33%
46.33%
Net Profit Margin
37.53%
37.53%
ROE
16.83%
16.83%
ROIC
-0.31%
0.31%

argenx SE (0QW0.L) Income Statement & Financial Overview

Explore comprehensive income reports for argenx SE 0QW0.L, broken down by year and quarter.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$1.30B$573.24M$841.96M$401.001M
Cost of Revenue$641.82M$59.07M$509.52M$43.18M
Gross Profit$661.43M$514.16M$332.44M$357.82M
Gross Profit Ratio$0.51$0.90$0.39$0.89
R&D Expenses$514.67M$235.94M$420.31M$224.97M
SG&A Expenses$563.64M$277.70M$254.28M$236.00M
Operating Expenses$548.27M$499.98M$462.09M$449.45M
Total Costs & Expenses$1.19B$559.05M$971.61M$492.63M
Interest Income$20.33M$40.59M$38.93M$38.90M
Interest Expense$704000.00$676000.00$572000.00$512000.00
Depreciation & Amortization$8.60M$74.51M$8.05M$24.05M
EBITDA$125.94M$88.70M-$118.50M-$54.53M
EBITDA Ratio$0.10$0.15-$0.14-$0.14
Operating Income$103.04M$14.19M-$129.65M-$93.42M
Operating Income Ratio$0.08$0.02-$0.15-$0.23
Other Income/Expenses (Net)-$16.53M$73.84M$46.24M$19.07M
Income Before Tax$86.51M$88.02M-$83.41M-$74.35M
Income Before Tax Ratio$0.07$0.15-$0.10-$0.19
Income Tax Expense-$687.65M-$3.39M-$52.57M-$12.75M
Net Income$835.54M$91.41M-$30.37M-$61.60M
Net Income Ratio$0.64$0.16-$0.04-$0.15
EPS$11.78$1.52-$0.51-$1.04
Diluted EPS$11.78$1.39-$0.51-$1.04
Weighted Avg Shares Outstanding$70.95M$60.09M$59.40M$59.31M
Weighted Avg Shares Outstanding (Diluted)$70.96M$65.76M$59.40M$59.31M

Over the last four quarters, argenx SE's revenue moved from $401.001M in Q1 2024 to $1.30B in Q4 2024. Operating income in Q4 2024 was $103.04M, with a strong operating margin of 8%. Despite fluctuations in R&D and SG&A expenses, EBITDA for argenx SE remained robust at $125.94M, reflecting operational efficiency. Net income rose to $835.54M, with an EPS of $11.78. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;